Iain Baird is an operating partner at Altaris and a board member of Padagis and Kindeva. Iain has a long track record of partnering with founders and management teams to build contract development and manufacturing organizations (CDMOs) and product companies including: OSO BioPharmaceuticals, CANbridge Life Sciences, Gallus Biopharmaceuticals, Brammer Bio, Mikart, Arranta Bio, Vibalogics, Genezen, Enterobiotix and Meridian Medical Technologies. Iain started his career at AstraZeneca (formerly ICI and Zeneca) where he designed and project managed the construction of pharmaceutical facilities and ran multiple production sites. Subsequently, Iain was a member of the leadership teams that established Avecia Oligonucleotides and Avecia Vaccines. Iain received a Bachelor of Engineering in Mechanical and Electrical Engineering from Robert Gordons University.
Tim Callahan is an operating partner at Altaris and a board member of CMP Pharma and Padagis. Tim has over 25 years of board and operational leadership experience in biopharmaceutical companies, including serving as SVP, Commercial Operations at Actavis Plc (now Allergan), where he led the commercial transformation of the brand division into a multi-billion-dollar global specialty business. Previously, he built specialty pharma businesses in commercial leadership roles at Actavis, Watson Pharmaceuticals, and Schein Pharmaceutical. Tim has held board roles in public, private, and non-profit healthcare organizations, and he has served as a Senior Advisor to McKinsey & Company. Tim holds a Bachelor of Science degree in Applied Economics and Business Management from Cornell University.
Shawn Cavanagh is an operating partner at Altaris and serves as Executive Chair of Kindeva and Meridian. Shawn has over 30 years of experience in the pharmaceutical services industry, predominantly with contract development and manufacturing organizations. Previously, Shawn was President, Chief Operating Officer, and member of the Board of Directors at Cambrex Corporation. Shawn has also held leadership roles at Lonza, where he served as President of Lonza Bioscience. He holds a degree in Chemical Engineering from the University of New Hampshire.
Bruce Friedman is an operating partner at Altaris with more than 45 years of experience in the pharmaceutical and diagnostic industries, most recently as Vice President, Technical Operations at Noven Pharmaceuticals. Bruce was a founder of JDS Pharmaceuticals, an Altaris operating company that was acquired by Noven Pharmaceuticals in 2007. Previously, Bruce worked at Pfizer, Carter-Wallace and MedPointe. Bruce has a bachelor and a master’s degree in Pharmaceutical Sciences from Columbia University.
Bernie Lyons is an operating partner at Altaris and a board member of Minnetronix. Previously, Bernie served as a board member of Creganna and Paramit prior to their sales. Bernie has over 30 years of experience in the medical device industry, including as the President & CEO of Direct Flow Medical, Inc. Prior to Direct Flow, he served as President and CEO of Vasca, Inc. and CardioClasp, Inc., and held several senior level positions at Boston Scientific. Bernie is an Executive in Residence with Canon USA and Partners Healthcare Innovation, and has served as an advisor/board member to numerous innovative medical device start-ups.
Greg Sargen is an operating partner at Altaris and chair of the audit committee at Kindeva Drug Delivery and Veranova. Greg has over 25 years of experience in the pharmaceutical services industry and has served on the board of two publicly traded biopharmaceutical companies. Previously, Greg was Executive Vice President and Chief Financial Officer, and Vice President of Corporate Development and Strategy at Cambrex Corporation, a publicly traded Contract Development and Manufacturing Organization. Greg also held finance roles at Fisher Scientific International (now ThermoFisher), Merck & Co and Expanets. Greg began his career in auditing at Deloitte & Touche, LLP, and is a Certified Public Accountant. Greg holds a B.S. in Accounting from Penn State University and an MBA from The Wharton School.
Phil Smith is an operating partner at Altaris and is Chair of the board of Intricon and a board member of Trean. Phil has over 30 years of board, strategic advisory and operational leadership experience in the healthcare industry, predominantly with medical device companies. Previously, Phil was a managing director at investment banking firms Kroll (formerly Duff & Phelps), BMO Capital Markets (formerly Greene Holcomb Fisher) and Piper Jaffray, where he advised healthcare clients and executed mergers, acquisitions and corporate finance transactions. Prior to his investment banking career, Phil held various executive leadership positions at several medical technology companies, including as President and CEO of Angeion Corporation, a global medical technology company focused on cardiorespiratory health solutions and DGIMED Ortho, an orthopedic trauma technology company. Phil also served as an Executive Vice President of Vital Images, a global medical imaging software company. Phil received a BS in Electrical Engineering from the University of Florida and an MBA from The Wharton School at the University of Pennsylvania.
Brooks West is an operating partner at Altaris. Brooks has over 25 years of board and operational leadership experience in the medical technology industry, including serving as President and CEO of BK Medical, an Altaris portfolio company. Previously, Brooks served for over a decade as a sell-side equity research analyst, most recently as a Senior Research Analyst covering medical technology at Piper Jaffray. Brooks received a Bachelor of Business Administration from Boston University.
- Analogic | Tom Ripp
- Chemical Computing Group | Paul Labute
- Clearwater | Steve Cagle
- CMP Pharma | Gerald Sakowski
- G&H Orthodontics | John Voskuil
- Intricon | Scott Longval
- Kindeva Drug Delivery | Milton Boyer
- Minnetronix | Jeremy Maniak
- Padagis | Pam Hoffman
- Solesis | Jeff Robertson
- Trean Insurance Group | Julie Baron
- Veranova | Mike Riley
Members of the Altaris Operating Network are not employees of Altaris.